Table 2.

DPP4i CV outcome trials

Drug (class)	Landmark name	Study population	Primary outcome	Dosing	Estimated enrollment	Duration (years)	End date	Identifier
Alogliptin	EXAMINE	T2DM with ACS (within >15 to < 90 days)	MACE	6.25 mg, 12.5 mg, or 25 mg qd‡	5,400	4.75	2013	NCT00968708
Saxagliptin	SAVOR TIMI 53	T2DM with multiple CRF‖	Composite	2.5 mg or 5 mg qd	16,500	4	2013	NCT01107886
Sitagliptin	TECOS	T2DM with preexisting CVD	Composite	50 mg or 100 mg qd‡	14,000	5	2014	NCT00790205
Linagliptin	CAROLINA	T2DM with preexisting CVD	Composite	5 mg qd	6,000	7.5	2018	NCT01243424
Linagliptin	CARMELINA	T2DM with impaired renal function or CVD	Composite	5 mg once daily	8,300	4.5	2018	NCT01897532
Omarigliptin (MK3102)	MK-3102-015 AM1	T2DM with inadequate glycemic control on diet/exercise therapy and oral antihyperglycemic agent monotherapy	Any adverse event	25 mg once weekly	585	1.5	2014	NCT01697592
Omarigliptin (MK3102)	MK-3102-018	T2DM with preexisting CVD	Composite	25 mg once weekly	4,000	5	2017	NCT01703208

CVD, cardiovascular disease; T2DM, type 2 diabetes; MACE, Major Adverse Cardiac Events (defined as a composite of CV death, nonfatal MI and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee); Composite, a composite defined as CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization